Kornimate/medical-research-clean huggingface dataset:
venous pressure measurement of the great saphenous vein using controlled compression ultrasound in healthy persons and patients with chronic venous disease as a new non invasive method for investigation of the pathophysiology in primary varicose veins

Conditions: Chronic Venous Insufficiency

Summary: part i: proof of concept trial to achieve normal venous pressure values under different provocation maneuvers in healthy persons part ii: non invasive measurement of venous pressure under different provocation maneuvers in patients with chronic venous disease


Eligibility criteria:
inclusion criteria: part i: * healthy persons without clinical signs of venous disease, informed consent part ii: * patients with chronic venous disease with complete incompetence of the great saphenous vein (hach iv) * informed consent exclusion criteria: part i: * clinical signs of venous disease, former deep vein thrombosis (dvt) part ii: * former deep vein thrombosis, former vein surgery
impact of a structured wellness behavioral intervention on quality of life in nmosd

Conditions: Neuromyelitis Optica Spectrum Disorder (NMOSD)

Summary: this project aims to study whether a structured wellness program intervention can improve quality of life among people living with neuromyelitis optica spectrum disorder (nmosd). this pilot will test a multi-modal wellness program tailored to nmosd patients that includes services from physical therapists, dietitians, social workers, nurse practitioners and cognitive therapists. the trial will be designed as a randomized controlled trial, randomizing patients to immediately starting the program as well as a 6 month delayed start. the intervention would leverage an existing clinical comprehensive ms wellness program at the corinne dickinson for multiple sclerosis (ms) at mount sinai medical center. the primary endpoint of this study would be evaluating quality of life, as assessed by ms-quality of life -54.

this pilot will aim to recruit 20 patients. participants will be randomized into one of two arms: the trial group will begin wellness program services and behavioral interventions immediately; the control group will participate in other educational activities, and begin wellness program services and behavioral interventions 6 months after randomization. the wellness intervention will include dietary, physical therapy, social work, and nurse practitioner evaluations, as well as behavioral counseling to implement recommendations. all participants will complete assessments, with patient-reported outcome surveys and objective assessments at baseline, 12 weeks, and 6 months for the core study. participants will also be offered the option of continuing into a one year extension study, wherein one additional wellness intervention and bimonthly behavioral counseling sessions will be offered until 12 months on study. study assessments will be completed at 12 months and 18 months to assess sustainability of the program. assessments will include subjective reports of quality of life as pertaining to living with their disease, mobility, vision, exercise, diet, as well as objective measures of motor and vision function.

Eligibility criteria:
inclusion criteria: * adults (age ≥18) with nmosd diagnosed with 2015 nmosd clinical criteria. * all edss scores will be considered in order to make the intervention accessible to all patients regardless of disability. * all patients regardless of treatment type will be considered. exclusion criteria: * age\<18 * inability to voluntarily provide consent for study participation * inability to participate in study evaluation and/or endpoint measures, or participation in another concurrent randomized controlled trial or wellness based intervention. * any patients with a relapse within 30 days of randomization or any patients with medical restrictions on physical activity will be excluded. * any patients who begin stimulants and/or dalfampridine between enrollment and randomization will be excluded.

Keywords: nmosd wellness diet physical therapy social work comprehensive
digital health physical activity program for older family care partners of patents with heart failure

Conditions: Heart Failure; Caregiver Burden

Summary: the purpose of the aim 3 study is to conduct a pilot randomized controlled trial to assess feasibility and preliminary effects of the tpa4you intervention.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 60 years * involved in caring for a household member aged 60 years or older with the new york heart association class ii, iii or iv hf * provide at least 10 hours/week of unpaid care for the past 6 months * physically able to engage in structured exercise such as walking, and upper body resistance exercises * engage in \< 30 min of moderate-intensity exercise on fewer than 3 days per week over the past 6 months * able to read, speak, and comprehend 5th grade english * own a smartphone * reachable by telephone, text messaging, and email exclusion criteria: * medical or functional conditions precluding participation in the physical activity (pa) components of the intervention (e.g., inability to walk one block or climb stairs without chest pain, shortness of breath, dizziness; history of falls; or serious or unstable cardiovascular or pulmonary disease) * cognitive impairment (telephone interview for cognitive status \[tics\]52 score \< 25) * inability to use technology * participation in a pa intervention in the previous 6 months * current participation in a pa or behavior change trial

Keywords: heart failure older adults family caregivers digital health physical activity
open-label extension of a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lovaza® and simvastatin therapy in hypertriglyceridemic subjects

Conditions: Hypertriglyceridemia

Summary: in a previous trial (lov111858/om6), subjects received in a double-blind fashion either 4 g/day of lovaza® (omega-3-ethyl esters) \[formerly known as omacor\] co-administered with simvastatin 40 mg/day or placebo co-administered with simvastatin 40 mg/day for 8 weeks. this extension trial, lov111818/om6x assessed the continued efficacy and safety of lovaza® (omega-3-ethyl esters) co-administered with simvastatin 40 mg vs. switching from simvastatin plus placebo to simvastatin plus lovaza® for lowering non-high density lipoprotein-cholesterol (non-hdl-c) levels at 4 months (primary endpoint) and additionally at 12 and 24 months.

two studies comprise this om6 program. study lov111858/om6 (double-blind study) which is outlined in nct00246701 and study lov111818/om6x (open-label extension) outlined in this posting.

Eligibility criteria:
for lov111818/om6x - subjects were included in the study if they had met all relevant inclusion/exclusion criteria prior to and throughout the double-blind study lov111858/om6 and completed study lov111858/om6 to week 8. fyi - entry criteria for lov111818/om6 (double-blind study) inclusion criteria: * men and women ages 18-79 years, inclusive * current therapy with a statin drug * triglyceride levels between 200 and 499 mg/dl * normally active and in good health on the basis of medical history, brief physical examination, electrocardiogram, and routine laboratory tests * provide written informed consent and authorization for protected health information disclosure exclusion criteria: * sensitivity to statin drugs or omega-3 fatty acids * lipoprotein lipase impairment or apo c-2 deficiency or type iii hyperlipidemia * unexplained muscle pain or weakness * history of pancreatitis * recent history of certain heart, kidney, liver, lung, or gastrointestinal diseases, or cancer (except non-melanoma skin cancer) * poorly controlled diabetes, or receiving insulin therapy * pregnant or lactating females. women of childbearing potential who are not using a medically approved method of contraception. * use of certain types of hormones, anticonvulsant drugs, immunologic drugs, antibiotic, antifungal and antiviral drugs, and cardiac drugs * use of warfarin (coumadin)

Keywords: high triglycerides lovaza simvastatin omega-3-acid ethyl esters
effects of in-home addiction treatment for first responders

Conditions: Substance Use Disorders

Summary: retrospective analysis to evaluate impact of an in-home addiction treatment program on first responders with substance use disorder.

the purpose of this retrospective study is to evaluate the effects of in-home addiction treatment on first responders with substance use disorder. treatment engagement, hospitalizations, detox and residential addiction treatment admissions, and lethal overdoses will be measured. although not the primary focus, recidivism and relapse will be measured.

Eligibility criteria:
inclusion criteria: * client is or has been a first responder * client enrolled in aware recovery care after april 2017 * client discharged from aware recovery care before march 2019 * client has primary substance use disorder diagnosis exclusion criteria: * client has never been first responder * client moved out of service area or lost insurance during care
assessing peer support for physical activity in women with hiv and hypertension

Conditions: HIV; Hypertension

Summary: this clinical trial will assess the acceptability and feasibility of a peer-supported behavioral physical activity intervention for women living with hiv and hypertension.

an individually randomized pilot trial (n=50) of an adapted behavioral physical activity (pa) intervention will be used to assess the feasibility and acceptability of providing exercise prescription, peer support, and home blood pressure monitoring to women ages 40+ living with hiv and hypertension. secondary outcomes to be assessed include systolic and diastolic blood pressure, pa time and intensity, pa self-efficacy, perceived social support, and health-related quality of life.

Eligibility criteria:
inclusion criteria: * woman living with hiv * age 40 and above * diagnosed with htn * access to a personal phone for study-related phone calls * willing to wear an accelerometer on their waist or hip for 7 days at beginning and end of 12-week intervention * able to ambulate independently * english speaking exclusion criteria: * pregnant * unable to provide informed consent due to cognitive deficit, serious mental illness, or active substance use

Keywords: women hiv hypertension physical activity behavioral clinical trial
the effect of eggs on postprandial metabolism

Conditions: Healthy

Summary: the objective of this randomized, double-blinded, placebo-controlled, 3-way crossover pilot study is to determine whether eggs can favorably alter biomarkers of postprandial metabolism when included with other cooked breakfast foods typically selected by older americans.


Eligibility criteria:
inclusion criteria: * men \& postmenopausal women, aged 50-70 years * bmi 28-34 kg/m2 exclusion criteria: * cigarette smoking and/or nicotine replacement use * individuals taking estrogen * use of cholesterol-lowering medications * use of blood pressure-lowering medications * regular use of any stomach acid-lowering medications or laxatives (including fiber supplements) * cardiovascular (heart) disease * gastrointestinal disease * kidney disease * endocrine disease: including diabetes, untreated thyroid disease * rheumatoid arthritis * active treatment for any type of cancer, except basal cell carcinoma, within 1 year prior to study admission * systolic blood pressure \> 150 mmhg and/or diastolic blood pressure \> 95 mmhg * regular use of oral steroids * regular daily intake of ≥ 2 alcoholic drinks * vegetarians * allergy to eggs * avoidance and/or intolerance of pork products * no dietary supplements, including those containing any vitamins, minerals,herbs, plant concentrates (including garlic, gingko, st. john's wort) homeopathic remedies, probiotics, or fish oil (including cod liver oil), for one month prior to study admission
factors related to the number of visits to pt in phc

Conditions: Musculoskeletal Diseases or Conditions

Summary: musculoskeletal disorders can be a large burden on individuals, health care and social care systems. the aim was to assess the feasibility of performing a prospective study investigating whether self-efficacy, fear of movement, empowerment or enablement has any relation to the number of visits to physiotherapists among patients with a musculoskeletal disorder in primary health care. design was approspective study with consecutively selection including patients seeking physiotherapist for the first time for a musculoskeletal disorder. primary outcome measure included operational and practical feasibility regarding recruitment of participants, use of questionnaires and key variables to be collected as part of the study.

background: musculoskeletal disorders can be a large burden on individuals, health care and social care systems. patients with musculoskeletal disorders are often treated by physiotherapists in primary health care. psychosocial variables can be a significant obstacle to recover from musculoskeletal injuries. the primary aim of this pilot study was to assess the feasibility of performing a prospective study investigating whether self-efficacy, fear of movement, empowerment or enablement has any relation to the number of visits to physiotherapist among patients with a musculoskeletal disorder in primary health care. methods: prospective study with consecutively selection including patients seeking physiotherapist for the first time for a musculoskeletal disorder. primary outcome measure included operational and practical feasibility regarding recruitment of participants, use of questionnaires and key variables to be collected as part of the study. secondary outcomes included correlation between self-efficacy (exercise self-efficacy scale (eses-s)), fear of movement (tampa scale for kinesiophobia (tsk-sv)), empowerment (making decisions scale ), enablement (patient enablement instrument (pei)) and number of visits to physiotherapist. statistical analysis was done using ibm spss statistics version 24 with analysis of correlation using spearman's rank correlation coefficient.

Eligibility criteria:
inclusion criteria: * patients, who seek physiotherapist for the first time for a musculoskeletal disorder, are over 18 years of age and are able to read, write and understand swedish. exclusion criteria: * patients, who have visited physiotherapist previous for the same musculoskeletal disorder and/or are diagnosed with malignant diseases. patients, who suffer from dementia, severe mental illness or other conditions making them not able to understand the information about the study and not able to fill in the questionnaires.

Keywords: physiotherapy musculoskeletal disorders self-efficacy empowerment enablement
18f-mfbg pet imaging in the evaluation of neuroblastoma

Conditions: Neuroblastoma

Summary: the aim of this study is to evaluate the diagnostic performance and tumor burden of 18f-metafluorobenzylguanidine (18f-mfbg) positron emission tomography (pet) in patients with neuroblastoma.

neuroblastoma highly expresses norepinephrine transporter (net) which is targeted by function alanalogue of norepinephrine, 123/131i-mlbg. however, low spatial resolution of 123/131i-mlbg and inaccurate attenuation correction of single photon emission tomography (spect/ct) will affect the image quality of mlbg spect and lead to poor diagnosis of small lesions. in addition, 123l-mlbg imaging is usually performed at 24h after injection, while 131i-mlbg is performed at 48h or even 72h after injection. the procedure is complicated and takes a long time, which limits clinical application. 18f-labeled mfbg is an ideal tracer to show the expression of net. preliminary data show that 18f-mfbg imaging is safe and has favorable biodistribution and kinetics with good targeting of lesions. patients can undergo pet 0.5 hours after injection without special preparation. our study will assess the safety profile, image quality and evaluate the diagnostic performance and tumor burden of 18f-mfbg. patients with suspected or histologically confirmed neuroblastoma will be enrolled in this study.

Eligibility criteria:
inclusion criteria: 1. age 0-18 years old, with legal guardian; 2. clinically suspected or confirmed patients with neuroblastoma; 3. if the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. if the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent. exclusion criteria: 1. patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases; 2. patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 msv. 3. patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month; 4. patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.
probiotics for diaper dermatitis

Conditions: Diaper Dermatitis

Summary: the goal of this randomized controlled clinical trial is to determine the effect of the probiotic omnibiotic® panda in treating diaper dermatitis in children under the age of two years. the main question it aims to answer is: is the probiotic omnibiotic® panda effective in reducing the duration of diaper dermatitis in children under the age of two years? researchers will compare the probiotic and placebo group to see if the duration of diaper dermatitis is significant among the two groups. participants will: * receive 6 droplets daily of probiotic or placebo for 3 weeks and * observe and record improvement of diaper rash symptoms each day using a diary.


Eligibility criteria:
inclusion criteria: * presence of diaper dermatitis * age less than two years exclusion criteria: * previous use of probiotics * age more than two years * an acute bacterial infection * chronic disease * local use of antibiotics in the anogenital region

Keywords: diaper dermatitis probiotics children
predictors of treatment outcome for smokers with and without schizophrenia

Conditions: Tobacco Dependence

Summary: the primary purpose of this investigation is to determine the predictive value of task persistence as measured by a mirror tracing task. a secondary purpose is to evaluate differences in task persistence in smokers with or without schizophrenia. it is hypothesized that task persistence in smokers in both diagnostic categories (schizophrenia and no schizophrenia) will predict tobacco dependence treatment outcome at one and six months. it is also hypothesized that smokers with schizophrenia will show lower levels of task persistence after controlling for other motor skills than smokers without schizophrenia.

please see brief summary above.

Eligibility criteria:
inclusion criteria: * current smokers must be over the age of 18, * must fit into the diagnostic groups schizophrenia / schizoaffective disorder; or the non-schizophrenia group. * must smoke at least 10 cigarettes per day * must be capable of giving informed consent as measured by folstein mini mental status exam of at least 22. exclusion criteria: * those unable to give informed consent. * psychotic disorders other than schizophrenia
immediate post-operative anesthesia with either lidocaine or bupivacaine

Conditions: Periodontal Diseases

Summary: immediate post-suturing administration of either one of two dental anesthetic solutions or a placebo prior to dismissal.

this study seeks to evaluate the pain response following the administration of two anesthetic solutions just prior to patient dismissal from a surgical procedure: 2% xylocaine with 1:100,000 epi and 0.5% bupivicaine with 1:200,000 epi in comparison with 0.9% normal saline as a placebo. the study team will monitor pain response following these interventions at 4, 8, 12, 24, and 48 hours.

Eligibility criteria:
inclusion criteria: -patients who have undergone a comprehensive periodontal evaluation and treatment plan not related to participation in this study and... 1. require flap surgery of 2 to 5 teeth in a continuous site (including flap debridement, flap osseous, extractions, and guided tissue regeneration (gtr) procedures), and... 2. require iv sedation and local anesthesia or local anesthesia only... 3. in either the maxillary or mandibular arch. exclusion criteria: 1. pregnancy, or those planning to become pregnant 2. allergy or any medical issue using lidocaine or bupivacaine 3. inability to take non-steroidal anti-inflammatory drugs (nsaids) or acetaminophen 4. non-english speaking 5. not possessing an i-phone or android device 6. patients requiring narcotic for iv sedation 7. patients requiring either iv or oral steroids during the perioperative period

Keywords: flap debridement flap osseous tooth extractions guided tissue regeneration iv sedation local anesthesia
comparative evaluation of covid-19 vaccines response

Conditions: COVID-19 Vaccines

Summary: study population population with vaccinated with three different covid vaccines (inactive vaccine (sinovac life sciences, beijing, china), recombinant human adenovirus serotype number 26 (rad26 of sputnik v), mrna vaccine (pfizer/biontec). this is multi center study, 5 centers will be joined to study from different part of the country. approximately 1500 people will be enrolled to study.

aim of study * to evaluate anti-sars-cov-2 igg antibody and neutralizing antibody response in different vaccine groups * to evaluate progression of the vaccine response after 2, 6, and 12 months after vaccination in different vaccine groups, and compare antibody response in different vaccines group. * it was also aimed to evaluate effect of the age, gender, co-morbid conditions such as copd, dm, heart failure, covid infection on igg antibody and neutralizing antibody response. anti sars cov2 igg antibody levels will be measured with chemiluminescence method (chem) by using advia centaur xp immunassay system (siemens helthcare, gmbh, germany) and anti sars cov2 igg reactive (siemens helthineers, gmbh, germany). neutralizing capacity of anti-sars-cov-2 antibodies against sars cov2 levels will be determined with elisa method (elx 808, elisa microplate absorbance reader, biotek instruments inc, winooski, vt, usa) by using euroimmun sars-cov-2 neutralisa assay (euroimmun, medizinische labordiagnostika ag, germany).

Eligibility criteria:
inclusion criteria: - any person, male or female, over 18 years of age. 1. the patient has signed an informed consent form. 2. the patient was vaccinated with sars-cov-2 vaccine. exclusion criteria: * inability to give clear information (person in an emergency, difficulty understanding the subject, etc.) * person under safeguard of justice * person under guardianship or curator ship.